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Abstract
Background: Breast cancer (BCa)-related mortality still remains the second leading cause of
cancer-related deaths worldwide. Patients with BCa have increasingly shown resistance and high
toxicity to current chemotherapeutic drugs for which identification of novel targeted therapies are
required.
Methods: To determine the effect of PDBD on BCa cells, estrogen-receptor positive (ER+)-MCF-
7 and estrogen-receptor negative (ER-)-MDA 231 cells were treated with PDBD and the cell
viability, apoptotic, cell cycle, Western blot and Promoter assays were performed.
Results: PDBD inhibits cell viability of ER+ and ER- BCa cells by inducing apoptosis without causing
significant toxicity in normal breast epithelial cells. While dissecting the mechanism of action of
PDBD on BCa, we found that PDBD inhibits Akt signaling and its downstream targets such as NF-
κB activation, IAP proteins and Bcl-2 expression. On the other hand, activation of JNK/p38 MAPK-
mediated pro-apoptotic signaling was observed in both ER+ and ER- BCa cells.
Conclusion: These findings suggest that PDBD may have wide therapeutic application in the
treatment of BCa.
Background
Patients with estrogen receptor-negative breast cancer (ER-
BCa) have a median survival of 10–12 months when com-
pared to patients with for ER-positive (ER+) BCa who have
a median survival of 40–48 months [1]. Limited effective-
ness of current chemotherapeutic drugs such as
tamoxifen, paclitaxel and docetaxel, shows severe side
effects in the BCa patients [2], these realities underscore
the importance of identifying novel targeted therapies
with minimal side effects to treat this deadly disease.
Akt plays a major role in the regulation of cell survival,
apoptosis, and oncogenesis [3]. Activation of Akt nega-
tively regulates the programmed cell death signaling
either by blocking or inhibiting the pro-apoptotic pro-
teins such as BAD, Forkhead transcription factors and
GSK-3β [3-5]. The observations from cell culture studies
suggests that activation of Akt leads to the phosphoryla-
tion of IKK which in turn results in NF-κB activation and
cell survival [6]. Akt regulates cell cycle by phosphorylat-
ing the cell cycle inhibitors p21 and p27 resulting in
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uncontrolled cell proliferation in various cell types [7-9].
Additionally, Akt increases cyclin D1 expression thereby
aiding cancer cell growth and proliferation [10].
Mitogen activated protein kinases (MAPKs) which are ser-
ine/threonine protein kinases involved in carcinogenesis
due to their ability to stimulate cell proliferation and sur-
vival [11]. Three major subfamilies have been described:
extracellular-regulated kinases (ERK), c-Jun N-terminal
kinase (JNK), and p38 kinase; depending on the cellular
context and stimulators these signaling pathways will be
activated following phosphorylation of downstream
events which will decide the fate of the cell. In the MAPK
pathway, the small G-protein, Ras activates Raf-1 which in
turn activates MEK-1 resulting in the activation of p44
(ERK1) and p42 (ERK2) which is known to cause cellular
proliferation and inhibit apoptosis [12]. However, grow-
ing evidence suggesting the dual role of the MEK/ERK
pathway in cell survival and apoptosis [13]. On the other
hand, JNK and p38 kinases are generally involved in the
regulation of pro-apoptotic signaling in many cell types
[14].
Current therapeutic modalities for BCa are usually associ-
ated with toxicity and side effects thereby indicating novel
targeted therapies are much needed. Recently, much
attention is being paid to natural compounds and several
groups have demonstrated their usefulness either for che-
moprevention or chemotherapy on BCa. The lack of
mechanistic details about these compounds has impeded
bringing them to the main stream of medicine for preven-
tion or treatment of BCa. Naturally occurring polyphe-
nolic antioxidants are recognized as one of the most
effective classes of cancer-preventive agents [15-17],
because they reduce oxidative stress a known contributor
to carcinogenesis with little or no systemic toxicity [18].
Work in our laboratory is focused on dissecting the mech-
anism of action of natural compounds and more impor-
tantly, to discover promising lead components for the
development of anti-cancer drugs that specifically target
BCa. Recently, we reported that a polyherbal medicine is
currently in practice as complementary and alternative
therapy for the treatment of BCa in the southern parts of
India [19], which were shown to inhibit ER+ and ER- BCa
cells in cell culture models [19]. We have isolated an
active ingredient, (8'Z)-3-pentadec-10-enyl-benzene-1, 2-
diol (PDBD) from this polyherbal mixture which has
proved to be effective on BCa cells [20]. This study is
focused on determining the molecular mechanism of
action of PDBD on BCa.
Methods
Cell lines
MCF-10A, MDA 231, MCF-7, ZR-75-1, Hs578T and MDA
435 cells were purchased from American Type Culture
Collection (Manassas, VA). All the cell lines were grown in
DMEM supplemented with 10% fetal bovine serum and
1% L-glutamine.
Natural compounds and caspase inhibitor
(8'Z)-3-pentadec-10-enyl-benzene-1, 2-diol (PDBD) was
the major compound isolated from Polyherbal mixture in
the Dr. Rohr's laboratory at the University of Kentucky
with a purity of 99.5% (Figure 1) [20]. Caspase-3 inhibi-
tor, zDEVD-CHO was purchased from Promega Corpora-
tion (Madison, WI).
Cell viability, Apoptotic assays and Cell Cycle analysis
Cells were treated with PDBD or vehicle (DMSO) for 24 h
at different concentrations and cell survival curve was
plotted using MTT assay [21]. Also, Annexin V-FITC stain-
ing assays and TUNEL assays were performed on five dif-
ferent BCa cells and treated with 4, 6 or 8 μM PDBD
followed by flowcytometric analysis as described earlier
[22,23]. Cell cycle analysis in MCF-7 and MDA 231 cells
was performed following treatment with PDBD (3 μM
and 2 μM respectively) using flow cytometric analysis as
described earlier [22].
Western Blot analysis
MDA 231 and MCF-7 cells were treated with PDBD (4 and
6 μM, respectively) for varying time intervals and cell
lysates were subjected to Western blot analysis using Akt,
ERK, pERK1/2, MEK-1, MEK-4, MEKK-1, pMEK-1/2,
pMEK-3/6, Bcl-2, survivin, cdk-2, cdk-4, cdk-6, cyclin D1,
cyclin E and NF-κB subunits p50, p55 and p65 from Santa
Cruz Biotechnology (Santa Cruz, CA); XIAP and Bcl-xL
from MBL International (Woburn, MA) and, pAkt (ser
473), PI3K p85 and Histone H3 from Cell signaling tech-
nology (Danvers, MA). β-actin and GAPDH from Santa
Cruz Biotechnology was used as the loading control.
Structure of [(8'Z)-3-pentadec-10-enyl-benzene-1, 2-diol (PDBD)Figure 1
Structure of [(8'Z)-3-pentadec-10-enyl-benzene-1, 2-
diol (PDBD).
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Kinase assay
PI3 kinase assay was also performed to determine the
effect of PDBD on PI3K expression and activity. PDBD-
and vehicle-treated cells were subjected to PI3 kinase
assay using colorimetry as described earlier [24].
ELISA for IκB-α activity
MDA 231 cells were treated with PDBD for 6 and 12
hours, and IκB-α activity was quantified using IκB-α
ELISA kit (Calbiochem, Gibbstown, NJ) as described ear-
lier [24].
ELISA studies for NF-κB activity
MDA 231 cells were treated with PDBD for 6 and 12
hours, and binding studies were performed to determine
the activity of NF-κB p65 subunit using universal EZ-TFA
transcription factor assay kit (Millipore, Bedford, MA) as
described earlier [25].
Transient transfection and luciferase assay
MDA 231 cells (at 70–80% confluency) were transiently
transfected using Lipofectamine plus reagents from Invit-
rogen Corporation (Carlsbad, CA) with 4 μg of the NF-κB
luciferase construct (containing two tandem repeats of
NF-κB-responsive sites) in the presence of a vector con-
taining Renilla luciferase to normalize transfection effi-
ciency as described earlier [26,27]. Transfected cells were
either left untreated or treated with PDBD as indicated
and the cells were harvested after 24 h to determine NF-κB
promoter activity.
Fluorometry for caspase-3 activation
MDA 231 cells were treated PDBD alone or caspase-3
inhibitor alone or a combination of both for 24 h and cas-
pase-3 activity was determined using the ApoAlert cas-
pase-3 fluorescent assay kit as described earlier [26].
Statistical analysis
all the experiments were performed three times to ascer-
tain reproducibility of the results and the data shown are
representative of three experiments. The student's t test
was used to calculate statistical significance.
Results
PDBD inhibits cell survival and induces apoptosis on ER+ 
and ER- BCa
To determine the anti cancer effect of PDBD, we con-
ducted cell viability and apoptotic assays on a panel of
ER+ (MCF-7 and ZR-75-1), ER- (MDA 231, MDA 435 and
Hs578T) BCa and normal breast epithelial (MCF-10A)
cells. As seen in figure 2A, MDA 231, Hs578t and ZR-75-1
cells were highly sensitive to PDBD when compared to
MCF-7 and MDA 435 cells. Interestingly, there was no sig-
nificant alteration in the viability of normal breast epithe-
lial cell line, MCF-10A suggesting that PDBD selectively
targets BCa cells.
To determine whether inhibition of cell viability by PDBD
is due to the induction of apoptosis, all the five BCa cell
lines (Hs578T, ZR-75-1, MCF-7, MDA 231 and MDA 435)
and normal breast epithelial cells (MCF-10A) were sub-
jected to Annexin V-FITC and TUNEL assays. PDBD at 8
μM concentration induced almost 100% apoptosis in
MDA 231, Hs578T and ZR-75-1 when compared to 56%
and 58% of apoptosis in MCF-7 and MDA 435 cells
respectively (Figure 2B). However, PDBD failed to induce
significant levels of apoptosis in the normal breast epithe-
lial cell line, MCF-10A (Figure 2B). The apoptotic index
was confirmed by Annexin-V-FITC/PI and TUNEL assays.
Role of PDBD in cell cycle regulation in BCa cells
We investigated whether PDBD plays a role in the regula-
tion of cell cycle and found that PDBD treatment induced
a strong G0/G1 cell cycle arrest observed in time depend-
ent manner. In MDA-231 cells, a G0/G1 phase of cell cycle
distribution was 64.5% at 12 h following treatment with
PDBD, 66.3% and 75.36% at 24 and 48 hours respectively
with a concomitant decrease in the percentage of cells in
the S and G2/M phase (Table 1). A similar G0/G1 arrest was
observed in MCF-7 cells following treatment with PDBD
(Data not shown).
Next, we examined whether PDBD regulates the expres-
sion of G0/G1 cell cycle proteins in MCF-7 and MDA 231
cells. As seen in figure 3, PDBD downregulated the expres-
sion of Cdk-2, Cdk-4 and Cdk-6 in a time dependent fash-
ion in both MCF-7 and MDA 231 cells. In addition, Cyclin
E and Cyclin D1 expressions were also downregulated fol-
lowing treatment with PDBD in both BCa cell lines. Col-
lectively these observations suggest that PDBD alters the
expression of G0/G1 regulatory proteins thereby causing
cell cycle arrest in BCa cells.
PDBD inhibits Akt signaling without altering PI3K activity 
in BCa cells
The protein kinase, Akt, functions as a molecular nexus for
a number of signaling pathways that regulate cell growth,
cell survival, and tumor progression, and its activity has
been implicated in the inhibition of apoptosis and pro-
motion of angiogenesis [28]. PDBD inhibited pAkt (ser
473) expression 6 h after treatment in MCF-7 cells,
whereas, in MDA-231 cells, inhibition of pAkt expression
was seen at 24 h after treatment. No alteration in total Akt
levels in MDA 231 cells were seen (Figure 4A). Then, we
determined whether PDBD targets the upstream event of
Akt, the PI3K and found that no alteration of either the
expression (upper panel) or activity (lower panel) of PI3
Kinase in BCa cells (Figure 4B) were seen suggesting that
PDBD specifically either Akt or its downstream signaling
BMC Cancer 2009, 9:41 http://www.biomedcentral.com/1471-2407/9/41
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A. BCa cells were treated with varying concentrations of PDBD for 24 h and MTT assay was performed to determine cell via-bilityFigure 2
A. BCa cells were treated with varying concentrations of PDBD for 24 h and MTT assay was performed to 
determine cell viability. Each data point represents the mean ± SD for four wells. B. PDBD induced apoptosis in BCa cells. 
Bar graph shows the percentage of apoptosis. The base-line apoptosis in the untreated group was normalized with data in the 
treated group. The data shown are representative of mean ± SD from three independent experiments.
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of BCa. While dissecting the effect of PDBD on Extracellu-
lar-regulated kinase (ERK) signaling, we found that grad-
ual upregulation of pERK expression was seen in MCF-7
and MDA 231 cells. Total ERK levels remained constant in
both the BCa cell lines following treatment with PDBD for
upto 24 h (Figure 5).
PDBD inhibits NF-κB activation in MDA 231 cells
Since there was no significant downregulation of pAkt
expression in MDA 231, we investigate whether the down-
stream events of Akt signaling are affected by PDBD.
Nuclear factor-κB is a transcription factor which is
involved in cell survival and proliferation and has been
established as one of the major downstream targets of Akt
[29]. PDBD down regulated NF-κB p65 activity (Figure
6A) and also inhibited NF-κB at the promoter level (Fig-
ure 6B) in MDA 231 cells. Then, we analyzed IκB status,
and our results suggest that PDBD is capable of maintain-
ing IκB-α in the non-phosphorylated form thereby inhib-
iting the nuclear translocation of the active NF-κB
subunits (Figure 6C). Also, as expected, a significant down
regulation of NF-κB subunits (p65, p55 and p50) in a
timely manner in the nuclear fraction suggesting that
PDBD effectively inhibits NF-κB activation (Figure 6D).
PDBD regulates Pro-Apoptotic and Pro-Survival Proteins 
in BCa
The Bcl-2 family of proteins and IAPs are a well estab-
lished class of proteins that are involved in the regulation
of cell survival and apoptosis [30]. In our results, PDBD
downregulates the expression of XIAP, Bcl-2, Bcl-xL and
survivin at 12 h onwards in MDA 231 cells, however, in
MCF-7 cells there were no changes in the expression levels
of Bcl-2, but survivin, Bcl-xL and XIAP were down-regu-
lated following treatment with PDBD at 24 h (Figure 7A).
The JNK and p38 MAP kinase pathway proteins are asso-
ciated with pro-survival as well as pro-apoptotic functions
[31] and therefore the expression levels of pJNK and pp38
were investigated. The up regulation of pJNK were found
from 3 h onwards in MCF-7 and MDA 231 cells, however,
pp38 was upregulated at 3 h in MCF-7 cells and at 12 h
MDA 231 cells (Figure 7B). Also, PDBD induced caspase-
3 activation (~3.1-fold) in MDA 231 cells (Figure 7C) sug-
Table 1: Effects of PDBD on cell cycle distribution of PDBD.
Cell cycle Treatments MDA 231 (in %)
12 h 24 h 48 h
G0/G1 phase UT 46.85 36.77 39.53
PDBD 64.53 66.33 75.36
S phase UT 33.49 56.66 54.71
PDBD 28.14 33.67 15.77
G2/M phase UT 4.15 6.57 5.76
PDBD 7.34 0.0 8.86
MCF-7 and MDA 231 cells were treated with PDBD and cell lysates were subjected to Western blot analysis using cdk-2, cdk-4, cdk-6, Cyclin D1 and Cyclin EFigure 3
MCF-7 and MDA 231 cells were treated with PDBD and cell lysates were subjected to Western blot analysis 
using cdk-2, cdk-4, cdk-6, Cyclin D1 and Cyclin E. β-actin was used as a loading control.
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A. MCF-7 and MDA 231 cells were treated with PDBD and cell lysates were subjected to Western blot analysis (upper panel) using pAkt (ser473) and AktFigure 4
A. MCF-7 and MDA 231 cells were treated with PDBD and cell lysates were subjected to Western blot analysis 
(upper panel) using pAkt (ser473) and Akt. Lower panel are the bar graphs representing the relative density of pAkt in 
MCF-7 and MDA 231 cells that were normalized with β-actin. B. MCF-7 and MDA 231 cell lysates were subjected to Western 
blot analysis (upper panel) or colorimetric assay (lower panel) using PI3K antibody.
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gesting that PDBD induces JNK- and p38-mediated pro-
apoptotic signaling in BCa.
Discussion
Discovery of active compounds from natural products
have gained enormous importance in the field of BCa
therapy. In the present study, we have identified a potent
compound PDBD from a polyherbal mixture which spe-
cifically targets BCa cells without causing adverse effects
on normal breast epithelial cells. Interestingly, our results
suggest that ZR-75-1 cells are more sensitive when com-
pared to MCF-7 cells, which may be due to the absence of
caspase-3 in MCF-7 cells. The difference in PDBD sensitiv-
ity in MDA 231 and MDA 435 cells may be due to the over
expression of Erb-B2 in MDA 435, which regulates cell
survival and proliferation in several cancer types including
BCa [32-35].
Dysregulation of the expression of the cyclins and cdks are
involved in cell cycle, and which has been found to be a
hallmark in various types of cancer. Cyclin D1, a compo-
nent subunit of Cdk-4 and Cdk-6, is a rate-limiting factor
in progression of cells through the first gap (G1) phase of
the cell cycle [36]. Downregulation of Cdk-2, Cdk-4, Cdk-
6, Cyclin E, Cyclin D1 expression by PDBD suggests that
it targets several cell cycle regulatory proteins in BCa cells.
The serine/threonine protein kinase, Akt, plays critical
role in mammalian cell survival and has been shown to be
activated in various cancers including BCa [37,38]. Some
clinical studies suggested that activation of Akt correlates
with HER-2 expression and these patients tend to have
higher rate of relapse to tamoxifen therapy [39-42].
Recent studies report 15%–30% of BCa patient's express
high pAkt levels which was associated with resistance to
chemotherapeutic agents. The ability of PDBD to inhibit
pAkt expression in our study suggests that either PDBD
alone or a combination of PDBD with other chemothera-
peutic agents like tamoxifen and doxorubicin may
enhance the therapeutic potential of current chemother-
apy drugs [43,44]. While dissecting the involvement of
PI3K-mediated Akt signaling, we found that PDBD fails to
alter the expression and kinase activity of PI3K in MCF-7
and MDA 231 cells. Though, MDA 231 cells were more
sensitive to PDBD when compared to MCF-7 cells, pAkt
expression was not significantly downregulated in MDA
231 cells suggesting that PDBD directly targets the down-
stream events of PI3K/Akt signaling in MDA 231 cells.
NF-κB activation regulates cell survival [45,46] and it also
simultaneously inhibits the expression of several pro-
apoptotic proteins in various cell types [3,47]. In our stud-
ies we found that PDBD inhibited phosphorylation of Akt
in MCF-7 cells when compared to MDA 231 cells; so we
intended to determine whether PDBD regulates Akt
downstream events which may possibly result in inhibi-
tion of cell survival. Several lines of evidence suggest a
constitutive overexpression of NF-κB in ER- BCa com-
MCF-7 and MDA 231 cells were treated with PDBD and subjected to Western blot analysis using pERK and ERKFigure 5
MCF-7 and MDA 231 cells were treated with PDBD and subjected to Western blot analysis using pERK and 
ERK. Lower panel are the bar graphs representing the relative density of pERK in MCF-7 and MDA 231 cells that were nor-
malized with β-actin.
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pared to ER+ BCa [48-50]. The p65 subunit of NF-κB is
overexpressed in most of the BCa cell lines and in BCa
tumor tissues [48]. Interestingly a higher percentage of
NF-κB activation (98.7%) was found in human BCa tis-
sues from Taiwanese women which was correlated with
higher percentage of patients with metastatic BCa [51]. In
our study, PDBD inhibited NF-κB activation at the pro-
moter and protein level in MDA 231 cells suggesting that
PDBD can be used as a potential therapeutic agent for
BCa. Several natural compounds have the ability to down-
regulate NF-κB activation and some of the compounds
that we investigated in our laboratory namely curcumin
[22], Withaferin A [26] and Psoralidin [24], also shown
the ability to downregulate the NF-κB activation in many
cancer types.
Increased expression of phosphorylated JNK and p38 by
PDBD in both MCF-7 and MDA 231 cells suggest that acti-
vated JNK and p38 play a role in the induction of apopto-
sis in BCa cells [52]. Descriptively, the inhibition of Akt
pathway and the simultaneous activation of p38/JNK
pathway may attribute to the anti cancer activity of PDBD
in BCa cells. It is important to investigate whether inhibi-
tion of cell proliferation and induction of apoptosis by
PDBD is associated with the down-regulation of pro-sur-
vival signaling. Our results suggest that PDBD downregu-
lates the expression of XIAP, Bcl-xL and surviving which
might lead to chemosensitization of BCa cells.
Conclusion
PDBD inhibits pro-survival signaling such as Akt, MEK
and NF-κB with a simultaneous induction of pro-apop-
totic proteins in the BCa cells resulting in inhibition of
cell survival and proliferation. Additionally, PDBD causes
a G0/G1 cell cycle arrest in both MDA 231 and MCF-7 cells
which is also an important aspect for the treatment of can-
A. MDA 231 cells treated with PDBD and subjected to NF-κB binding assay and NF-κB p65 activity was studied to determine DNA binding activityFigure 6
A. MDA 231 cells treated with PDBD and subjected to NF-κB binding assay and NF-κB p65 activity was studied 
to determine DNA binding activity. B. MDA 231 cells were transiently transfected with NF-κB-luc, treated with varying 
concentrations of PDBD for 24 h and reporter studies were performed to determine NF-κB promoter activity. pRL-TK was 
used as the rennilla control plasmid. C. MDA 231 cells were treated with PDBD and lysates were subjected to either Western 
blot analysis (upper panel) or ELISA (lower panel) for expression profile of non-phosphorylated IκB-α. D. Nuclear and cyto-
plasmic fractions were obtained from MDA-231 cells, which were subjected to Western blot analysis using NF-κB p50, p55 
and p65. β-actin was used as the loading control for cytoplasmic fraction and Histone H3 was used as the loading control for 
nuclear fraction.
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A. MDA 231 cells treated with PDBD and cell lysates were subjected to Western blot analysis using XIAP, Bcl-xL, Bcl-2 and survivinFigure 7
A. MDA 231 cells treated with PDBD and cell lysates were subjected to Western blot analysis using XIAP, Bcl-
xL, Bcl-2 and survivin. B. Western blot analysis using pp38, pJNK, JNK-1 expression in MCF-7 and MDA 231 cells. C. MDA 
231 cells were treated with PDBD alone, caspase inhibitor alone or a combination of PDBD and caspase inhibitor for varying 
time intervals and were subjected to caspase-3 activation studies using flourometric assay.
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cer. Collectively our results suggest that further investiga-
tion of PDBD in vivo models may help bring this potent
molecule into the main stream of medicine for the treat-
ment of BCa.
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